Drug Type Small molecule-drug conjugates |
Synonyms CBP 1018, CBP1018 |
Target |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists), TRPV6 antagonists(Transient receptor potential cation channel subfamily V member antagonists), Immunomodulators |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 04 Nov 2021 | |
Lung Cancer | Phase 1 | CN | 05 Nov 2020 | |
Prostatic Cancer | Phase 1 | CN | 05 Nov 2020 | |
Bone metastases | Phase 1 | CN | - | |
Metastatic castration-resistant prostate cancer | IND Approval | US | 12 Jun 2024 |
NCT04928612 (ESMO2024) Manual | Phase 1 | 93 | CBP-1018 0.14 mg/kg | azvzlxafrv(mabnurkasg) = not yet reached bhlqsfuofl (bgnykvbzkn ) View more | Positive | 15 Sep 2024 | |
Phase 1 | 20 | jlbkkqmoti(fmxsftqaot) = zthbvuedkx ukirvzvjmp (wpftisnrrx ) View more | Positive | 22 Oct 2023 | |||
Phase 1 | 14 | chawzxjhzg(hfujycrpyu) = kwghnzluko qyyiaphdck (rkdjowojbz ) View more | Positive | 26 May 2023 | |||
(mCRPC) | wmpwiszqcd(ylicapmbxx) = xpewgjdztf mjlazdmcgu (wsgnqqwhic ) View more |